BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Epitomics, Inc. Receives Notice of Allowance from the United States Patent and Trademark Office for a Novel Method for Identifying Differentially Expressed Proteins


11/1/2011 6:24:21 AM

BURLINGAME, Calif., Nov. 1, 2011 /PRNewswire/ -- Epitomics, Inc., a California based biotech company, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for its Method for Identifying Differentially Expressed Proteins (application 10/705,109). The Notice allowed 17 claims for detection of differentially expressed proteins in cell samples using libraries of antibodies. This method has several potentially broad applications in the research and drug discovery markets, especially in the field of cancer.

"We are very excited to be granted the claims of this novel method," stated Dr. Guo-Liang Yu, Chief Executive Officer. "This is another step towards building a world class intellectual property estate around our unique and proprietary rabbit monoclonal technology. We look forward to continued success in the development of our technology and patents, and ultimately to providing the best antibodies and solutions to researchers and clinicians."

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity, specificity and bioactivity both in vitro and in vivo. Epitomics, Inc. is headquartered in Burlingame, California, and operates wholly owned subsidiaries in Hong Kong and Hangzhou, the People's Republic of China. For more information about Epitomics, please visitwww.epitomics.com

SOURCE Epitomics, Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->